There are currently 42 clinical trials in Oceanside, California looking for participants to engage in research studies. Trials are conducted at various facilities, including Excell Research, Inc, Excell Research, Dermatology Specialists Inc. and North County Clinical Research. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
A Study to Assess the Safety and Efficacy of Oral LPCN 1154A in Women With Severe PPD
NCT06979544
Recruiting
The purpose of this research study is to test the study drug, LPCN 1154A, as a possible treatment for postpartum depression (PPD). The trial aims to determine: * If LPCN 1154A reduces depressive symptoms in subjects with severe PPD * How well LPCN 1154A is tolerated and what side effects it may cause * If LPCN 1154A reduces anxiety symptoms in subjects with severe PPD
Gender:
FEMALE
Ages:
Between 15 years and 45 years
Trial Updated:
06/18/2025
Locations: Excell Research, Inc., Oceanside, California
Conditions: Depression, Postpartum, Depression, Post-Partum, Postpartum Depression (PPD), Post-Natal Depression, Peripartum Depression, Postnatal Depression
Register for Updates
A Randomized Study of Azetukalner Versus Placebo in Major Depressive Disorder
NCT06775379
Recruiting
X-NOVA2 is a Phase 3, multicenter, randomized, double-blind, placebo-controlled study to evaluate the clinical efficacy, safety, and tolerability of azetukalner as a monotherapy in adult participants diagnosed with Major Depressive Disorder (MDD)
Gender:
ALL
Ages:
Between 18 years and 74 years
Trial Updated:
06/18/2025
Locations: Excell Research Inc., Oceanside, California
Conditions: Major Depressive Disorder
Register for Updates
Fasedienol Nasal Spray for the Acute Treatment of Anxiety in Adults With Social Anxiety Disorder (PALISADE-3)
NCT06358651
Recruiting
This U.S. Phase 3 clinical trial is designed to evaluate the efficacy, safety, and tolerability of the acute intranasal (i.n.) administration of Fasedienol Nasal Spray (fasedienol) (3.2 µg) to relieve symptoms of acute anxiety in adult subjects ages 18 through 65 with Social Anxiety Disorder induced by a public speaking challenge (PSC) in a clinical setting. In addition, safety and tolerability of i.n. administration of 3.2 µg of fasedienol, as-needed, up to 6 times per day for up to 12 months,... Read More
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
06/17/2025
Locations: Vistagen Clinical Site, Oceanside, California
Conditions: Social Anxiety Disorder
Register for Updates
Study of ABX-002 for the Adjunctive Treatment of Major Depressive Disorder (AMPLIFY)
NCT06633016
Recruiting
The goal of this clinical trial is to learn if ABX-002 added to an existing antidepressant treatment will benefit depression symptoms in adults with moderate to severe major depressive disorder who have had an inadequate response to their antidepressant. This is a double-blind, placebo-controlled, 2-arm, parallel-group, Phase 2 study, randomized 1:1 (ABX-002: placebo). The study will include the following stages: 1. Screening, approximately 35 days 2. 42-day Treatment Period 3. 2-week post do... Read More
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
06/17/2025
Locations: Autobahn Site #106, Oceanside, California
Conditions: Major Depressive Disorder
Register for Updates
An Extension Study to Assess Long-Term Safety and Tolerability of Adjunctive KarXT in Subjects With Inadequately Controlled Symptoms of Schizophrenia
NCT05304767
Recruiting
This is a Phase 3, multicenter, 52-week, outpatient, open-label extension (OLE) study to evaluate the long-term safety and tolerability of adjunctive KarXT in subjects with schizophrenia with an inadequate response to their current antipsychotic treatment who previously completed the treatment period (Visit 8/Day 42 ± 3) of ARISE Study (KAR-012). The primary objective of the study is to assess the long-term safety and tolerability of adjunctive KarXT (a fixed dose combination of xanomeline and t... Read More
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
06/17/2025
Locations: Excell Research, Inc., Oceanside, California
Conditions: Schizophrenia
Register for Updates
A Study to Evaluate Safety and Efficacy of Empasiprubart in Adults With Dermatomyositis
NCT06284954
Recruiting
This study will evaluate the safety and efficacy of empasiprubart compared with placebo in adult participants with dermatomyositis (DM). The study duration will be approximately 92 weeks for all participants. After the screening period, eligible participants will be randomized in a 2:1 ratio to receive either empasiprubart or placebo, respectively, during the treatment period (duration of 25 weeks). At the end of the treatment period, all the participants will enter a safety follow-up period (d... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/13/2025
Locations: Profound Research LLC, Oceanside, California
Conditions: Dermatomyositis, Myositis
Register for Updates
Efficacy of BNC210 in Acute, As-needed Treatment of Anxiety in Social Anxiety Disorder - 1
NCT06510504
Recruiting
The purpose of the study is to evaluate the effect of a single, acute dose of BNC210 compared to placebo on reducing the severity of anxiety provoked by a behavioral assessment task and measured using the Subjective Units of Distress Scale (SUDS) in adult patients with social anxiety disorder.
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
04/15/2025
Locations: AFFIRM-1 Study Site, Oceanside, California
Conditions: Social Anxiety Disorder
Register for Updates
Descartes-08 for Patients With Systemic Lupus Erythematosus
NCT06038474
Recruiting
This is a Phase II study to evaluate the safety, tolerability and manufacturing feasibility of Descartes-08 CAR T-cells in patients with Systematic Lupus erythematosus (SLE).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/14/2025
Locations: Profound Research LLC, Oceanside, California
Conditions: Systemic Lupus Erythematosus (SLE)
Register for Updates
A Clinical Study That Will Measure How Well SEP-363856 Works and How Safe it is in Adults With Generalized Anxiety Disorder
NCT05729373
Recruiting
A clinical study that will meaure how well SEP-363856 works and how safe it is in adults with Generalized Anixety Disorder. This study will be accepting both male and female subjects between the ages of 18 years and 65 years old. The study will be held in Approximately 50 global study centers and approximately 15 additional centers for a separate Japan population. Participation in the study can be up to approximately 12 weeks.
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
04/09/2025
Locations: Excell Research, Inc., Oceanside, California
Conditions: Generalized Anxiety Disorder
Register for Updates
Efficacy and Safety Study of Adjunctive Troriluzole in Obsessive Compulsive Disorder
NCT04641143
Recruiting
The study's purpose is to evaluate the efficacy and safety of troriluzole as adjunctive therapy compared to placebo in subjects with Obsessive Compulsive Disorder (OCD)
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
03/07/2025
Locations: Excell Research, Inc, Oceanside, California
Conditions: Obsessive-Compulsive Disorder
Register for Updates
Study of ITI-1284 as an Adjunctive Treatment in Patients With Generalized Anxiety Disorder
NCT06480383
Recruiting
This is a multicenter, randomized, double-blind, placebo-controlled study evaluating the efficacy, safety, and tolerability of ITI-1284 compared with placebo as adjunctive therapy to GAD treatment in patients meeting Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, Text Revision (DSM-5-TR) criteria for GAD who have an inadequate response to ongoing GAD treatment.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/19/2025
Locations: Clinical Site, Oceanside, California
Conditions: Generalized Anxiety Disorder
Register for Updates
Study of ITI-1284 as Monotherapy Treatment in Patients With Generalized Anxiety Disorder
NCT06701903
Recruiting
This is a multicenter, randomized, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of ITI-1284 as monotherapy treatment in patients meeting Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, Text Revision (DSM-5-TR) criteria for GAD in patients who have had inadequate response to generalized anxiety disorder treatment.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/19/2025
Locations: Clinical Site, Oceanside, California
Conditions: Generalized Anxiety Disorder
Register for Updates